Peptide questions · MOTS-c
MOTS-c side effects: what studies and users report
Reviewed Evidence: EmergingPublished by PepVault
The library lists two common side effects for MOTS-c, injection site reaction and mild fatigue first week, and a safety note; the library’s evidence on it includes controlled trials in people.
Its safety note opens: MOTS-c is a mitochondrial-derived peptide regulating glucose and metabolic homeostasis; animal toxicology has been favorable at studied doses, but it has not been established as safe in humans: FDA (April 2026) says it has found no human exposure data for MOTS-c by any route and flags a possible risk of immune reactions to compounded versions.
What is commonly reported with MOTS-c
- Injection site reaction
- Mild fatigue first week
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 18) |
|---|---|
| Injection site reaction | 4: Epitalon, SS-31, Pinealon, Klotho |
| Mild fatigue first week | None: listed for MOTS-c alone |

Which MOTS-c side effects the longevity group shares
Across the 19 longevity compounds in the library, the effects listed most often are injection site reaction (5 of 19), injection-site discomfort (3 of 19), injection-site redness or itch (3 of 19) and mild headache (3 of 19). MOTS-c shares 1 of its 2 listed effects with at least one other longevity compound; mild fatigue first week is listed for MOTS-c alone.
What the MOTS-c safety notes say
The library’s safety note
MOTS-c is a mitochondrial-derived peptide regulating glucose and metabolic homeostasis; animal toxicology has been favorable at studied doses, but it has not been established as safe in humans: FDA (April 2026) says it has found no human exposure data for MOTS-c by any route and flags a possible risk of immune reactions to compounded versions. Community-reported effects include transient fatigue (often in the first 1-3 weeks), mild injection-site reactions, and occasional GI upset or palpitations. Because it influences glucose metabolism, glucose-relevant monitoring is a reasonable topic for your clinician. Long-term human safety is unknown.
The library’s interaction note
No published human interaction studies exist. Because MOTS-c affects glucose and insulin sensitivity, a mechanism-based consideration applies when combined with insulin or other antidiabetic agents, and glucose monitoring is worth discussing with a clinician. It is frequently stacked with GLP-1 agonists for metabolic goals — no combination-specific human data exists. No documented interaction with SSRIs, anticoagulants, or thyroid meds.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the MOTS-c reports come from
The library rates the evidence on MOTS-c as emerging: mostly preclinical, with limited human data.
Of the library’s 6 research notes on MOTS-c, 5 rest on animal studies and 1 on community reports.
Our 12 study pages on MOTS-c: 7 animal studies (mice), 3 animal studies (rats), 1 cell study (INS-1E and αTC-1 pancreatic cell lines) and 1 randomized trial.
So MOTS-c has controlled trials in people to set its listed effects against.
Questions people ask
What are the side effects of MOTS-c?
The library lists two common side effects for MOTS-c, injection site reaction and mild fatigue first week, and a safety note; the library’s evidence on it includes controlled trials in people.
Do MOTS-c’s side effects come from human studies?
The library rates the evidence on MOTS-c as emerging, and the library’s evidence on it includes controlled trials in people.
Which MOTS-c side effects are its own?
Among the longevity compounds, the library lists mild fatigue first week for MOTS-c alone.
Does MOTS-c interact with other medicines?
The library’s interaction note on MOTS-c begins: No published human interaction studies exist.